CN105050601A - 利用tor激酶抑制剂治疗前列腺癌 - Google Patents

利用tor激酶抑制剂治疗前列腺癌 Download PDF

Info

Publication number
CN105050601A
CN105050601A CN201380066349.9A CN201380066349A CN105050601A CN 105050601 A CN105050601 A CN 105050601A CN 201380066349 A CN201380066349 A CN 201380066349A CN 105050601 A CN105050601 A CN 105050601A
Authority
CN
China
Prior art keywords
pyrazin
dihydropyrazino
methyl
pyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380066349.9A
Other languages
English (en)
Chinese (zh)
Inventor
黛博拉·莫特森
希瑟·雷蒙
拉玛·K·娜尔拉
克里斯汀·梅·海格
金柏莉·伊丽莎白·富尔茨
辻俊哉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Priority to CN201910935268.7A priority Critical patent/CN110721186A/zh
Publication of CN105050601A publication Critical patent/CN105050601A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380066349.9A 2012-10-18 2013-10-17 利用tor激酶抑制剂治疗前列腺癌 Pending CN105050601A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910935268.7A CN110721186A (zh) 2012-10-18 2013-10-17 利用tor激酶抑制剂治疗前列腺癌

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
US61/715,510 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910935268.7A Division CN110721186A (zh) 2012-10-18 2013-10-17 利用tor激酶抑制剂治疗前列腺癌

Publications (1)

Publication Number Publication Date
CN105050601A true CN105050601A (zh) 2015-11-11

Family

ID=50023830

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380066349.9A Pending CN105050601A (zh) 2012-10-18 2013-10-17 利用tor激酶抑制剂治疗前列腺癌
CN201910935268.7A Pending CN110721186A (zh) 2012-10-18 2013-10-17 利用tor激酶抑制剂治疗前列腺癌

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910935268.7A Pending CN110721186A (zh) 2012-10-18 2013-10-17 利用tor激酶抑制剂治疗前列腺癌

Country Status (19)

Country Link
US (1) US20140113904A1 (https=)
EP (1) EP2908814B1 (https=)
JP (3) JP2015534981A (https=)
KR (2) KR102267927B1 (https=)
CN (2) CN105050601A (https=)
AU (1) AU2013202768B2 (https=)
BR (1) BR112015008834A2 (https=)
CA (1) CA2888609C (https=)
EA (1) EA029164B1 (https=)
ES (1) ES2777936T3 (https=)
IL (1) IL238326B (https=)
MX (1) MX368407B (https=)
MY (1) MY176599A (https=)
NI (1) NI201500055A (https=)
PH (2) PH12020550858A1 (https=)
SG (2) SG11201502999YA (https=)
UA (1) UA117000C2 (https=)
WO (1) WO2014062878A2 (https=)
ZA (1) ZA201503105B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110403943A (zh) * 2019-08-19 2019-11-05 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物
CN114702495A (zh) * 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367386A (zh) * 2001-12-08 2002-09-04 云南大学 一种人体全血或血清总psa值、总psa灰区值检测方法及前列腺癌检测试纸
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
SG10201500511TA (en) * 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367386A (zh) * 2001-12-08 2002-09-04 云南大学 一种人体全血或血清总psa值、总psa灰区值检测方法及前列腺癌检测试纸
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114702495A (zh) * 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
CN110403943A (zh) * 2019-08-19 2019-11-05 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Also Published As

Publication number Publication date
US20140113904A1 (en) 2014-04-24
ZA201503105B (en) 2016-11-30
JP2015534981A (ja) 2015-12-07
IL238326A0 (en) 2015-06-30
AU2013202768B2 (en) 2015-11-05
UA117000C2 (uk) 2018-06-11
KR20150070319A (ko) 2015-06-24
EP2908814B1 (en) 2019-12-25
JP2021050213A (ja) 2021-04-01
NI201500055A (es) 2015-09-10
KR102267927B1 (ko) 2021-06-21
SG10201810575WA (en) 2019-01-30
AU2013202768A1 (en) 2014-05-08
ES2777936T3 (es) 2020-08-06
EA201590744A1 (ru) 2015-11-30
IL238326B (en) 2018-03-29
PH12020550858A1 (en) 2023-02-20
MX368407B (es) 2019-10-02
JP7162543B2 (ja) 2022-10-28
EP2908814A2 (en) 2015-08-26
KR102157914B1 (ko) 2020-09-18
CA2888609C (en) 2020-12-01
PH12015500867A1 (en) 2015-06-22
JP2019081771A (ja) 2019-05-30
WO2014062878A3 (en) 2014-06-26
MY176599A (en) 2020-08-18
EA029164B1 (ru) 2018-02-28
KR20200108923A (ko) 2020-09-21
CN110721186A (zh) 2020-01-24
CA2888609A1 (en) 2014-04-24
WO2014062878A2 (en) 2014-04-24
WO2014062878A9 (en) 2014-12-18
MX2015004874A (es) 2015-08-05
BR112015008834A2 (pt) 2017-07-04
SG11201502999YA (en) 2015-05-28
PH12015500867B1 (en) 2015-06-22

Similar Documents

Publication Publication Date Title
JP6470821B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
CN104870998B (zh) 对作为TOR激酶抑制活性标记的PRAS40、GSK3‑β或P70S6K1的磷酸化抑制
JP7162543B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2019108368A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
AU2015213397B2 (en) Treatment of cancer with TOR kinase inhibitors
HK40013177A (en) Treatment of prostate cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1213049B (en) Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151111